Caris Life Sciences, Irving, Texas, has launched MI FOLFOXai, an artificial intelligence (AI)-based predictor of response to FOLFOX chemotherapy in metastatic colorectal cancer, which has demonstrated approximately 50% improvement in overall survival across two independent validation studies.
FOLFOX is a chemotherapy regimen for the treatment of colorectal cancer. It combines the drugs folinic acid (leucovorin), FOL; Fluorouracil (5-FU), F; and oxaliplatin (eloxatin), OX. Using Caris Molecular Intelligence tumor profiling results, MI FOLFOXai is intended to gauge a patient’s likelihood of benefiting from FOLFOX as a first-line regimen in combination with bevacizumab.


W. Michael Korn, MD, Caris Life Sciences.

MI FOLFOXai was validated using two independent datasets to compare the increased benefit arm to the decreased benefit arm. The first study was a blinded, prospective analysis using  retrospectively tested samples from the randomized Phase III Tribe2 study. This study showed a median overall survival improvement of 6.9 months. The second study involved several hundred cases with real-world evidence that showed a median overall survival increase of 11.8 months.

“FOLFOX is part of an NCCN guidelines recommended first-line treatment regimen for the roughly 35,000 patients in the United States newly diagnosed with metastatic colorectal cancer each year,” says W. Michael Korn, MD, chief medical officer at Caris. “Initiating the most appropriate therapy at this stage can be critical to successfully altering the course of disease. Clinical outcomes from MI FOLFOXai validations represent a mean overall survival of nearly 50%, making it imperative to get this information to patients and their physicians as soon as possible.”

For more information, visit Caris Life Sciences.